NCT06673069View on ClinicalTrials.gov

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2027

Conditions
Alzheimer DiseaseDown Syndrome
Interventions
DRUG

ION269

Administered as intrathecal (IT) injection.

Trial Locations (6)

40536

Ionis Investigative Site, Lexington

46202

Ionis Investigative Site, Indianapolis

53705

Ionis Investigative Site, Madison

63110

Ionis Investigative Site, St Louis

66205

Ionis Investigative Site, Kansas City

08041

Ionis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY